About US
Contact us
-
AstraZeneca scores injunction to temporarily halt former exec's start at crosstown rival GSKAstraZeneca has logged a last-minute victory—for now—in its executive tug of war with GSK. Just hours before outgoing AZ exec Chris Sheldon was set to take up his post at crosstown rival2022/9/1
-
Bayer’s BlueRock inks cardiovascular cell therapy delivery dealBayer’s BlueRock Therapeutics haspartneredwith BioCardia on the delivery of cell therapies, paying a “sizable” upfront fee to access minimally invasive technology that could get its heart failure can2022/9/1
-
Amid launch efforts, Neurocrine doles out £48M to acquire small UK biotech DiurnalAs Neurocrine Biosciences grows through U.S.drug launches, the company is simultaneouslyaiming to expand its global reach with a small buyout. Neurocrine Biosciences shelled out £48.3 (ap2022/8/30
-
Amgen's Lumakras triumphs in confirmatory trial, threatening Mirati's accelerated approval windowAmgen has bagged the first randomized clinical trial win in the KRAS inhibitor class of cancer medicines. But for potential runner-up Mirati Therapeutics, it could bode ill beyond just a temporary da2022/8/30
-
Bavarian Nordic ramps up monkeypox vaccine manufacturing capacity, reopens bulk facilityBavarian Nordic has been scrambling to ramp up supply of the only approved monkeypox vaccine, Jynneos, to meet growing global demand. The Danish company’s latest efforts include exploring reusing tec2022/8/26
-
Johnson & Johnson lost to Pfizer in bidding war for Global Blood Therapeutics: BloombergBefore settling on a $5.4 billion price tag for Global Blood Therapeutics, Pfizer had to fight off a mysterious “company A.” Now, the identity of that contender has been revealed. Johnson2022/8/26
-
Pfizer partner CStone explores sale as US path blocked, Chinese competition heats up: BloombergA Pfizer cancer drug partner in China is considering a sale as the biotech’s commercial path in the U.S. looks uncertain and competition in its home country intensifies. CStone Pharmaceut2022/8/24
-
Eisai's oncology unit cut; WuXi, Samsung expansions; BeiGene, Novartis' PD-1 pivotEisai is shutting down an oncology venture for good. Continuing the recent CDMO expansion spree,Wuxi Biologics is plotting a $1.4 billion R&D and manufacturingsite in Singapore, just as Samsung B2022/8/24
-
Pisgah Labs to spend $55M to upgrade North Carolina facilityPisgah Laboratories, an API maker, will invest$55 millionto upgrade its manufacturing facility in Pisgah Forest, North Carolina, to include sterile injectables and liquid filling operations.2022/8/22
-
Takeda's cancer drug woes; Merck's 2nd Kelun ADC deal; Astellas' cell and gene therapy hubTakeda's oncology department has been hit hard thanks to U.S. generic entry to Velcadeand other problems. Merck signs a near-$1 billion deal with Kelun Biotech for the Chinese biotech's antibody-drug2022/8/22